ReAlta Life Sciences Overview

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $30M

  • Investors
  • 9

ReAlta Life Sciences General Information

Description

Developer of drugs intended to save lives by rebalancing the inflammatory response to address life-threatening acute and rare diseases. The company's peptides are based on research into the human astrovirus, which causes non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system and leveraging these virus-derived mechanisms to rebalance complement and inflammatory processes in the body, enabling healthcare professionals to address medical needs through beneficial inhibition of the complement system and inflammatory mechanisms.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5665 Lowery Road
  • Suite 100
  • Norfolk, VA 23502
  • United States
+1 (757)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 5665 Lowery Road
  • Suite 100
  • Norfolk, VA 23502
  • United States
+1 (757)

ReAlta Life Sciences Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ReAlta Life Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) 06-Nov-2023 $30M Completed Clinical Trials - Phase 2
6. Later Stage VC (Series A) 13-Sep-2023 Completed Clinical Trials - Phase 2
5. Grant 08-Jun-2021 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series A3) 28-Apr-2021 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 21-Apr-2020 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 28-Oct-2019 $12M $12M Completed Clinical Trials - General
1. Grant 06-Jun-2019 $4.4M Completed Clinical Trials - General
To view ReAlta Life Sciences’s complete valuation and funding history, request access »

ReAlta Life Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A5
Series A4
Series A3 428,327 $0.010000 $52.53 $52.53 1x $52.53 12.95%
Series A 764,706 $0.010000 $34 $34 1x $34 23.13%
To view ReAlta Life Sciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ReAlta Life Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drugs intended to save lives by rebalancing the inflammatory response to address life-threatening acute and
Drug Discovery
Norfolk, VA
25 As of 2024

Burnaby, Canada
 

Maastricht, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ReAlta Life Sciences Competitors (63)

One of ReAlta Life Sciences’s 63 competitors is Qu Biologics, a Venture Capital-Backed company based in Burnaby, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Qu Biologics Venture Capital-Backed Burnaby, Canada
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
Evommune Venture Capital-Backed Palo Alto, CA
Visterra Formerly VC-backed Waltham, MA
Mozart Therapeutics Venture Capital-Backed Seattle, WA
You’re viewing 5 of 63 competitors. Get the full list »

ReAlta Life Sciences Patents

ReAlta Life Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022286333-A1 Peptides and methods of use Pending 01-Jun-2021
CA-3215620-A1 Peptides and methods of use Pending 01-Jun-2021
US-20240209036-A1 Peptides and methods of use Pending 01-Jun-2021
EP-4346866-A1 Peptides and methods of use Pending 01-Jun-2021
AU-2022286333-A9 Peptides and methods of use Pending 01-Jun-2021 C07K14/08
To view ReAlta Life Sciences’s complete patent history, request access »

ReAlta Life Sciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ReAlta Life Sciences Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Koa Labs Venture Capital Minority
Children's Research Holdings Other Minority
Eriko Life Science Ventures Venture Capital Minority
Marathon Pharmaceuticals Corporation Minority
Commonwealth Research Commercialization Fund Government
You’re viewing 5 of 9 investors. Get the full list »

ReAlta Life Sciences FAQs

  • Where is ReAlta Life Sciences headquartered?

    ReAlta Life Sciences is headquartered in Norfolk, VA.

  • What is the size of ReAlta Life Sciences?

    ReAlta Life Sciences has 25 total employees.

  • What industry is ReAlta Life Sciences in?

    ReAlta Life Sciences’s primary industry is Drug Discovery.

  • Is ReAlta Life Sciences a private or public company?

    ReAlta Life Sciences is a Private company.

  • What is the current valuation of ReAlta Life Sciences?

    The current valuation of ReAlta Life Sciences is .

  • What is ReAlta Life Sciences’s current revenue?

    The current revenue for ReAlta Life Sciences is .

  • How much funding has ReAlta Life Sciences raised over time?

    ReAlta Life Sciences has raised $90.5M.

  • Who are ReAlta Life Sciences’s investors?

    Koa Labs, Children's Research Holdings, Eriko Life Science Ventures, Marathon Pharmaceuticals, and Commonwealth Research Commercialization Fund are 5 of 9 investors who have invested in ReAlta Life Sciences.

  • Who are ReAlta Life Sciences’s competitors?

    Qu Biologics, Cristal Therapeutics, Evommune, Visterra, and Mozart Therapeutics are some of the 63 competitors of ReAlta Life Sciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »